A bio-artificial renal epithelial cell system conveys survival advantage in a porcine model of septic shock

Journal of Tissue Engineering and Regenerative Medicine

Volumn 11, Issue 3, 2017, Pages 649-657

  Westover, Angela J ^a   Buffington, Deborah A ^a   Johnston, Kimberly A ^a   Smith, Peter L ^a   Pino, Christopher J ^a   Humes, H David ^a,b  

^a Innovative BioTherapies Inc   (United States)

^b UNIVERSITY OF MICHIGAN   (United States)

Author keywords

acute kidney injury; artificial kidney; capillary leak syndrome; immunotherapy; septic shock; systemic inflammatory response syndrome; tissue therapy

Indexed keywords

ARTIFICIAL ORGANS; CELLS; COPYRIGHTS; ESCHERICHIA COLI; INJECTION MOLDING; MEDICAL APPLICATIONS; PATIENT TREATMENT;

ACUTE KIDNEY INJURY; ARTIFICIAL KIDNEY; BIOARTIFICIAL; CAPILLARY LEAK SYNDROME; CELL SYSTEM; IMMUNOTHERAPY; RENAL EPITHELIAL CELLS; SEPTIC SHOCKS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROMES; TISSUE THERAPY;

CYTOLOGY;

CARBON; NIOBIUM; CYTOKINE;

ACUTE KIDNEY FAILURE; ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BIOARTIFICIAL RENAL EPITHELIAL CELL SYSTEM; COHORT ANALYSIS; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; EPITHELIUM CELL; ESCHERICHIA COLI; FEEDBACK SYSTEM; HEART OUTPUT; HUMAN; HUMAN CELL; INTENSIVE CARE UNIT; KIDNEY TUBULE EPITHELIUM; NONHUMAN; SEPTIC SHOCK; STEM CELL; ULTRAFILTRATION; UROLOGICAL EQUIPMENT; ANIMAL; ARTIFICIAL ORGAN; BLOOD; BLOOD PRESSURE; DISEASE MODEL; HEMATOCRIT; HEMODYNAMICS; KAPLAN MEIER METHOD; KIDNEY; KIDNEY FUNCTION TEST; MICROBIOLOGY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; PIG; SURVIVAL ANALYSIS;

ANIMALS; ARTIFICIAL ORGANS; BLOOD PRESSURE; CYTOKINES; DISEASE MODELS, ANIMAL; EPITHELIAL CELLS; ESCHERICHIA COLI; HEMATOCRIT; HEMODYNAMICS; KAPLAN-MEIER ESTIMATE; KIDNEY; KIDNEY FUNCTION TESTS; SHOCK, SEPTIC; SURVIVAL ANALYSIS; SUS SCROFA;

EID: 85015034296     PISSN: 19326254     EISSN: 19327005     Source Type: Journal    
DOI: 10.1002/term.1961     Document Type: Article

References (34)

1. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. 1992; Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 20(6): 864–874.
2. Bosmann M, Ward PA. 2013; The inflammatory response in sepsis. Trends Immunol 34(3): 129–136.
3. Buffington DA, Pino CJ, Chen L et al. 2012; Bioartificial renal epithelial cell system (BRECS): a compact, cryopreservable extracorporeal renal replacement device. Cell Med 4(1): 33–43.
4. Buffington DA, Westover AJ, Johnston KA et al. 2014; The bioartificial kidney. Transl Res 163(4): 342–351.
5. Chertow GM, Levy EM, Hammermeister KE et al. 1998; Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 104(4): 343–348.
6. Ding F, Song JH, Jung JY et al. 2011; A biomimetic membrane device that modulates the excessive inflammatory response to sepsis. PLoS One 6(4): e18584.
7. Fahy GM, Wowk B, Wu J. 2006; Cryopreservation of complex systems: the missing link in the regenerative medicine supply chain. Rejuvenat Res 9(2): 279–291.
8. Fissell WH, Dyke DB, Weitzel WF et al. 2002; Bioartificial kidney alters cytokine response and hemodynamics in endotoxin-challenged uremic animals. Blood Purif 20(1): 55–60.
9. Fissell WH, Lou L, Abrishami S et al. 2003; Bioartificial kidney ameliorates Gram-negative bacteria-induced septic shock in uremic animals. J Am Soc Nephrol 14(2): 454–461.
10. Giamarellos-Bourboulis EJ, Raftogiannis M. 2012; The immune response to severe bacterial infections: consequences for therapy. Expert Rev Anti Infect Ther 10(3): 369–380.
11. Humes HD. 1995; Acute renal failure: prevailing challenges and prospects for the future. Kidney Int Suppl 50: S26–S32.
12. Humes HD. 2000; Bioartificial kidney for full renal replacement therapy. Semin Nephrol 20(1): 71–82.
13. Humes HD, Buffington DA, MacKay SM et al. 1999a; Replacement of renal function in uremic animals with a tissue-engineered kidney. Nat Biotechnol 17(5): 451–455.
14. Humes HD, MacKay SM, Funke AJ et al. 1999b; Tissue engineering of a bioartificial renal tubule assist device: in vitro transport and metabolic characteristics. Kidney Int 55(6): 2502–2514.
15. Humes HD, Fissell WH, Weitzel WF. 2002a; The bioartificial kidney in the treatment of acute renal failure. Kidney Int Suppl 80: 121–125.
16. Humes HD, Fissell WH, Weitzel WF et al. 2002b; Metabolic replacement of kidney function in uremic animals with a bioartificial kidney containing human cells. Am J Kidney Dis 39(5): 1078–1087.
17. Humes HD, Weitzel WF, Bartlett RH et al. 2003a; Renal cell therapy is associated with dynamic and individualized responses in patients with acute renal failure. Blood Purif 21(1): 64–71.
18. Humes HD, Buffington DA, Lou L et al. 2003b; Cell therapy with a tissue-engineered kidney reduces the multiple-organ consequences of septic shock. Crit Care Med 31(10): 2421–2428.
19. Institute for Laboratory Animal Research, Clark JD, Gebhart GF, Gonder JC, Keeling ME, Kohn DF. 1996. The 1996 Guide for the Care and Use of Laboratory Animals ILAR J (1997) 38(1): 41–48. doi: 10.1093/ilar.38.1.4
20. Jekarl DW, Lee SY, Lee J et al. 2013; Procalcitonin as a diagnostic marker and IL-6 as a prognostic marker for sepsis. Diagn Microbiol Infect Dis 75(4): 342–347.
21. Kato S, Chmielewski M, Honda H et al. 2008; Aspects of immune dysfunction in end-stage renal disease. Clin J Am Soc Nephrol 3(5): 1526–1533.
22. Landray MJ, Wheeler DC, Lip GY et al. 2004; Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney disease: the chronic renal impairment in Birmingham (CRIB) study. Am J Kidney Dis 43(2): 244–253.
23. Levy MM, Fink MP, Marshall JC et al. 2003; 2001 SCCM/ESICM/ACCP/ATS/SIS: international sepsis definitions conference. Crit Care Med 31(4): 1250–1256.
24. Mao H, Katz N, Ariyanon W et al. 2013; Cardiac surgery-associated acute kidney injury. Cardiorenal Med 3(3): 178–199.
25. Martin GS, Mannino DM, Eaton S et al. 2003; The epidemiology of sepsis in the United States from 1979 through 2000. N Engl J Med 348(16): 1546–1554.
26. Osuchowski MF, Welch K, Siddiqui J et al. 2006; Circulating cytokine/inhibitor profiles reshape the understanding of the SIRS/CARS continuum in sepsis and predict mortality. J Immunol 177(3): 1967–1974.
27. Peng ZY, Wang HZ, Carter MJ et al. 2012; Acute removal of common sepsis mediators does not explain the effects of extracorporeal blood purification in experimental sepsis. Kidney Int 81(4): 363–369.
28. Pierrakos C, Vincent JL. 2010; Sepsis biomarkers: a review. Crit Care 14(1): R15.
29. Roberts RL, Hatori N, Drury JK et al. 1987; Purification and properties of porcine polymorphonuclear cells. J Immunol Methods 103(1): 27–32.
30. Tariq A, Izhar K, Simpson W et al. 2007; Incidence and outcomes in acute kidney injury: a comprehensive population-based study. J Am Soc Nephrol 18: 1021–1022.
31. Tumlin J, Wali R, Williams W et al. 2008; Efficacy and safety of renal tubule cell therapy for acute renal failure. J Am Soc Nephrol 19(5): 1034–1040.
32. Vincent JL, Rello J, Marshall J et al. 2009; International study of the prevalence and outcomes of infection in intensive care units. J Am Med Assoc 302(21): 2323–t12329.
33. Waikar SS, Curhan GC, Wald R et al. 2006; Declining mortality in patients with acute renal failure, 1988–2002. J Am Soc Nephrol 17(4): 1143–1150.
34. Westover AJ, Buffington DA, Humes HD. 2012; Enhanced propagation of adult human renal epithelial progenitor cells to improve cell sourcing for tissue-engineered therapeutic devices for renal diseases. J Tissue Eng Regen Med 6(8): 589–597.